Compare UG & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UG | RVPH |
|---|---|---|
| Founded | 1942 | 2006 |
| Country | United States | United States |
| Employees | N/A | 14 |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.2M | 29.2M |
| IPO Year | 1995 | N/A |
| Metric | UG | RVPH |
|---|---|---|
| Price | $6.25 | $0.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $66.67 |
| AVG Volume (30 Days) | 2.8K | ★ 2.6M |
| Earning Date | 05-07-2026 | 03-30-2026 |
| Dividend Yield | ★ 7.99% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.20 | N/A |
| Revenue | ★ $12,181,971.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $32.40 | ★ N/A |
| Revenue Growth | ★ 11.91 | N/A |
| 52 Week Low | $5.58 | $0.17 |
| 52 Week High | $9.88 | $3.11 |
| Indicator | UG | RVPH |
|---|---|---|
| Relative Strength Index (RSI) | 40.87 | 44.83 |
| Support Level | $5.58 | $0.32 |
| Resistance Level | $6.78 | N/A |
| Average True Range (ATR) | 0.13 | 0.25 |
| MACD | -0.03 | -0.16 |
| Stochastic Oscillator | 21.92 | 22.34 |
United-Guardian Inc manufactures and markets cosmetic ingredients, pharmaceuticals, medical lubricants, and specialty industrial products. Its product portfolio includes Klensoft, Deselex, Renacidin, Lubrajel Fluid. The company's pharmaceutical products are sold to and distributed by full-line drug wholesalers throughout the United States. Its medical and specialty industrial products are sold directly by the company to the end-users of those products or, in some cases, to contract manufacturers used by some of those end users. It operates in one business segment and its current product lines are separated into four distinct product categories that are cosmetic ingredients, pharmaceuticals, medical lubricants and sexual wellness. It derives key revenue from the sales made in the U.S.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.